Solaris Pharma Corporation located in Bridgewater, New Jersey announces final approval from U.S Food and Drug Administration for its Abbreviated New Drug Application for Clobetasol Propionate Cream USP, 0.05% in the following packaging configurations, 15 g, 30 g, 45 g and 60 g tubes. For more updates, please feel free to email us info@solaris-pharma.com
top of page
Search
Recent Posts
See AllSolaris Pharma Corporation is pleased to announce the product approval of Tazarotene Gel, 0.05% and 0.1%.
Solaris Pharma Corporation located Bridgewater, New Jersey announces the final approval from U.S Food and Drug Administration for its...
bottom of page
Comments